Industry Newsclinical trialoncologyimmunomefda approval
Immunome Reports Positive Phase 3 Results
7.2
Immunome, Inc. reported positive topline results from the Phase 3 RINGSIDE trial on December 15, showing an 84% reduction in likelihood of death or disease progression among 156 patients. About 56% experienced tumor shrinkage or disappearance versus 9% on placebo, and the company plans an FDA filing for Varegacestat in Q2 2026. The results spurred analyst price-target increases and a 48% three-month share gain.
Key Points
- 1Announces Phase 3 topline results showing 84% reduction in progression or death in 156 patients
- 2Drives analyst upgrades and price-target increases, signaling commercial expectations for Varegacestat approval
- 3Implies FDA filing in Q2 2026 and substantial market upside; practitioners monitor regulatory timeline
Scoring Rationale
Strong Phase 3 topline and analyst upgrades drive high impact, but relevance is limited to a niche oncology market.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
